Biopharmaceutical CMO and CRO Market Share, Global Industry Growth, Analysis, Size and Forecast 2024-2032
Description
The Biopharmaceutical CMO and CRO Market Size accounted for USD 34.7 Billion in 2023 and is estimated to achieve a market size of USD 61.5 Billion by 2032 growing at a CAGR of 6.6% from 2024 to 2032.
The biopharmaceutical industry has witnessed tremendous growth in recent years, fueled by advancements in biotechnology, the increasing prevalence of chronic diseases, and a heightened focus on personalized medicine. Central to this growth are the outsourcing partnerships formed with Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs). These partnerships enable biopharmaceutical companies to streamline operations, reduce costs, and accelerate the development and production of novel therapies. The Biopharmaceutical CMO and CRO Market is a dynamic sector that plays a pivotal role in the success of pharmaceutical innovation. This abstract provides an in-depth overview of the current trends, growth drivers, market segmentation, and the future outlook of the biopharmaceutical CMO and CRO market.
Contract Manufacturing Organizations (CMOs) are companies that provide outsourced services for the manufacturing of drugs, including active pharmaceutical ingredients (APIs) and finished dosage forms. These organizations assist biopharmaceutical companies by managing complex production processes, from drug development to commercial-scale manufacturing. Similarly, Contract Research Organizations (CROs) offer outsourced services for drug discovery, preclinical research, clinical trials, and regulatory submissions. CROs support biopharmaceutical companies in all stages of drug development, providing specialized expertise in regulatory affairs, clinical research, data management, and clinical trial monitoring.
Biopharmaceutical CMO and CRO Market Segmentation
The worldwide market for biopharmaceutical CMO and CRO is split based on source, service type product, and geography.
Biopharmaceutical CMO and CRO Sources
Non-Mammalian
Mammalian
Biopharmaceutical CMO and CRO Service Types
Contract Manufacturing
Process Development
Upstream
Downstream
Analytical & QC studies
Finish & Fill Operations
Packaging
Contract Research
Oncology
Cardiology
Neuroscience
Inflammation & Immunology
Others
Biopharmaceutical CMO and CRO Products
Biosimilars
Biologics
Monoclonal Antibodies (MAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biopharmaceutical CMO and CRO Market Regional Outlook
North America (United States and Canada)
Europe (Germany, UK, France, Spain, and the Rest of Europe.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Rest of Asia-Pacific)
Latin America (Brazil, Mexico, and the Rest of Latin America.)
Middle East and Africa (South Africa, GCC Countries, and, the Rest of the Middle East & Africa (ME&A))
Biopharmaceutical CMO and CRO Market Players
Some of the top biopharmaceutical CMO and CRO companies offered in our report includes Catalent, Inc., Lonza Group AG, Patheon N.V., Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd., Samsung Biologics, Boehringer Ingelheim GmbH, Cytovance Biologics, Inc., AbbVie Contract Manufacturing, Fujifilm Diosynth Biotechnologies, and AGC Biologics.
The biopharmaceutical industry has witnessed tremendous growth in recent years, fueled by advancements in biotechnology, the increasing prevalence of chronic diseases, and a heightened focus on personalized medicine. Central to this growth are the outsourcing partnerships formed with Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs). These partnerships enable biopharmaceutical companies to streamline operations, reduce costs, and accelerate the development and production of novel therapies. The Biopharmaceutical CMO and CRO Market is a dynamic sector that plays a pivotal role in the success of pharmaceutical innovation. This abstract provides an in-depth overview of the current trends, growth drivers, market segmentation, and the future outlook of the biopharmaceutical CMO and CRO market.
Contract Manufacturing Organizations (CMOs) are companies that provide outsourced services for the manufacturing of drugs, including active pharmaceutical ingredients (APIs) and finished dosage forms. These organizations assist biopharmaceutical companies by managing complex production processes, from drug development to commercial-scale manufacturing. Similarly, Contract Research Organizations (CROs) offer outsourced services for drug discovery, preclinical research, clinical trials, and regulatory submissions. CROs support biopharmaceutical companies in all stages of drug development, providing specialized expertise in regulatory affairs, clinical research, data management, and clinical trial monitoring.
Biopharmaceutical CMO and CRO Market Segmentation
The worldwide market for biopharmaceutical CMO and CRO is split based on source, service type product, and geography.
Biopharmaceutical CMO and CRO Sources
Non-Mammalian
Mammalian
Biopharmaceutical CMO and CRO Service Types
Contract Manufacturing
Process Development
Upstream
Downstream
Analytical & QC studies
Finish & Fill Operations
Packaging
Contract Research
Oncology
Cardiology
Neuroscience
Inflammation & Immunology
Others
Biopharmaceutical CMO and CRO Products
Biosimilars
Biologics
Monoclonal Antibodies (MAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biopharmaceutical CMO and CRO Market Regional Outlook
North America (United States and Canada)
Europe (Germany, UK, France, Spain, and the Rest of Europe.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Rest of Asia-Pacific)
Latin America (Brazil, Mexico, and the Rest of Latin America.)
Middle East and Africa (South Africa, GCC Countries, and, the Rest of the Middle East & Africa (ME&A))
Biopharmaceutical CMO and CRO Market Players
Some of the top biopharmaceutical CMO and CRO companies offered in our report includes Catalent, Inc., Lonza Group AG, Patheon N.V., Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd., Samsung Biologics, Boehringer Ingelheim GmbH, Cytovance Biologics, Inc., AbbVie Contract Manufacturing, Fujifilm Diosynth Biotechnologies, and AGC Biologics.
Table of Contents
250 Pages
- CHAPTER 1. Industry Overview of Biopharmaceutical CMO and CRO Market
- 1.1. Definition and Scope
- 1.2. Summary
- CHAPTER 2. Research Approach
- 2.1. Methodology
- 2.2. Data Source
- CHAPTER 3. Market Dynamics And Competition Analysis
- 3.1. Market Drivers
- 3.2. Restraints and Challenges
- 3.3. Growth Opportunities
- 3.4. Porter’s Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitute
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
- 3.5. Market Concentration Ratio and Market Maturity Analysis of Biopharmaceutical CMO and CRO Market
- 3.5.1. Go To Market Strategy
- 3.5.1.1. Introduction
- 3.5.1.2. Growth
- 3.5.1.3. Maturity
- 3.5.1.4. Saturation
- 3.5.1.5. Possible Development
- 3.6. Technological Roadmap for Biopharmaceutical CMO and CRO Market
- 3.7. Value Chain Analysis
- 3.7.1. List of Key Manufacturers
- 3.7.2. List of Customers
- 3.7.3. Level of Integration
- 3.8. Cost Structure Analysis
- 3.8.1. Price Trend of Key Raw Materials
- 3.8.2. Raw Material Suppliers
- 3.8.3. Proportion of Manufacturing Cost Structure
- 3.8.3.1. Raw Material
- 3.8.3.2. Labor Cost
- 3.8.3.3. Manufacturing Expense
- 3.9. Regulatory Compliance
- 3.10. Competitive Landscape, 2023
- 3.10.1. Player Positioning Analysis
- 3.10.2. Key Strategies Adopted By Leading Players
- CHAPTER 4. Manufacturing Plant Analysis
- 4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2023
- 4.2. R&D Status of Major Manufacturers in 2023
- CHAPTER 5. Biopharmaceutical CMO and CRO Market By Source
- 5.1. Introduction
- 5.2. Biopharmaceutical CMO and CRO Revenue By Source
- 5.2.1. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast, By Source, 2020-2032
- 5.2.2. Non-Mammalian
- 5.2.2.1. Non-Mammalian Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 5.2.3. Mammalian
- 5.2.3.1. Mammalian Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- CHAPTER 6. Biopharmaceutical CMO and CRO Market By Service Type
- 6.1. Introduction
- 6.2. Biopharmaceutical CMO and CRO Revenue By Service Type
- 6.2.1. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast, By Service Type, 2020-2032
- 6.2.2. Contract Manufacturing
- 6.2.2.1. Contract Manufacturing Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.2.2. Process Development
- 6.2.2.2.1. Process Development Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.2.2.2. Upstream
- 6.2.2.2.2.1. Upstream Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.2.2.3. Downstream
- 6.2.2.2.3.1. Downstream Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.2.3. Analytical & QC studies
- 6.2.2.3.1. Analytical & QC studies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.2.4. Finish & Fill Operations
- 6.2.2.4.1. Finish & Fill Operations Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.2.5. Packaging
- 6.2.2.5.1. Packaging Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.3. Contract Research
- 6.2.3.1. Contract Research Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.3.2. Oncology
- 6.2.3.2.1. Oncology Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.3.3. Cardiology
- 6.2.3.3.1. Cardiology Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.3.4. Neuroscience
- 6.2.3.4.1. Neuroscience Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.3.5. Inflammation & Immunology
- 6.2.3.5.1. Inflammation & Immunology Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 6.2.3.6. Others
- 6.2.3.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- CHAPTER 7. Biopharmaceutical CMO and CRO Market By Product
- 7.1. Introduction
- 7.2. Biopharmaceutical CMO and CRO Revenue By Product
- 7.2.1. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast, By Product, 2020-2032
- 7.2.2. Biosimilars
- 7.2.2.1. Biosimilars Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 7.2.3. Biologics
- 7.2.3.1. Biologics Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 7.2.3.2. Monoclonal Antibodies (MAbs)
- 7.2.3.2.1. Monoclonal Antibodies (MAbs) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 7.2.3.3. Recombinant Proteins
- 7.2.3.3.1. Recombinant Proteins Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 7.2.3.4. Vaccines
- 7.2.3.4.1. Vaccines Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 7.2.3.5. Antisense, RNAi, & Molecular Therapy
- 7.2.3.5.1. Antisense, RNAi, & Molecular Therapy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- 7.2.3.6. Others
- 7.2.3.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
- CHAPTER 8. North America Biopharmaceutical CMO and CRO Market By Country
- 8.1. North America Biopharmaceutical CMO and CRO Market Overview
- 8.2. U.S.
- 8.2.1. U.S. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 8.2.2. U.S. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 8.2.3. U.S. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 8.3. Canada
- 8.3.1. Canada Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 8.3.2. Canada Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 8.3.3. Canada Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 8.4. North America PEST Analysis
- CHAPTER 9. Europe Biopharmaceutical CMO and CRO Market By Country
- 9.1. Europe Biopharmaceutical CMO and CRO Market Overview
- 9.2. U.K.
- 9.2.1. U.K. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 9.2.2. U.K. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 9.2.3. U.K. Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 9.3. Germany
- 9.3.1. Germany Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 9.3.2. Germany Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 9.3.3. Germany Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 9.4. France
- 9.4.1. France Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 9.4.2. France Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 9.4.3. France Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 9.5. Spain
- 9.5.1. Spain Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 9.5.2. Spain Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 9.5.3. Spain Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 9.6. Rest of Europe
- 9.6.1. Rest of Europe Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 9.6.2. Rest of Europe Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 9.6.3. Rest of Europe Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 9.7. Europe PEST Analysis
- CHAPTER 10. Asia Pacific Biopharmaceutical CMO and CRO Market By Country
- 10.1. Asia Pacific Biopharmaceutical CMO and CRO Market Overview
- 10.2. China
- 10.2.1. China Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 10.2.2. China Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 10.2.3. China Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 10.3. Japan
- 10.3.1. Japan Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 10.3.2. Japan Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 10.3.3. Japan Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 10.4. India
- 10.4.1. India Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 10.4.2. India Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 10.4.3. India Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 10.5. Australia
- 10.5.1. Australia Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 10.5.2. Australia Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 10.5.3. Australia Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 10.6. South Korea
- 10.6.1. South Korea Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 10.6.2. South Korea Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 10.6.3. South Korea Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 10.7. Rest of Asia-Pacific
- 10.7.1. Rest of Asia-Pacific Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 10.7.2. Rest of Asia-Pacific Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 10.7.3. Rest of Asia-Pacific Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 10.8. Asia Pacific PEST Analysis
- CHAPTER 11. Latin America Biopharmaceutical CMO and CRO Market By Country
- 11.1. Latin America Biopharmaceutical CMO and CRO Market Overview
- 11.2. Brazil
- 11.2.1. Brazil Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 11.2.2. Brazil Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 11.2.3. Brazil Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 11.3. Mexico
- 11.3.1. Mexico Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 11.3.2. Mexico Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 11.3.3. Mexico Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 11.4. Rest of Latin America
- 11.4.1. Rest of Latin America Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 11.4.2. Rest of Latin America Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 11.4.3. Rest of Latin America Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 11.5. Latin America PEST Analysis
- CHAPTER 12. Middle East & Africa Biopharmaceutical CMO and CRO Market By Country
- 12.1. Middle East & Africa Biopharmaceutical CMO and CRO Market Overview
- 12.2. GCC
- 12.2.1. GCC Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 12.2.2. GCC Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 12.2.3. GCC Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 12.3. South Africa
- 12.3.1. South Africa Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 12.3.2. South Africa Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 12.3.3. South Africa Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 12.4. Rest of Middle East & Africa
- 12.4.1. Rest of Middle East & Africa Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Source, 2020-2032
- 12.4.2. Rest of Middle East & Africa Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Service Type, 2020-2032
- 12.4.3. Rest of Middle East & Africa Biopharmaceutical CMO and CRO Revenue (USD Million) and Forecast By Product, 2020-2032
- 12.5. Middle East & Africa PEST Analysis
- CHAPTER 13. Player Analysis Of Biopharmaceutical CMO and CRO Market
- 13.1. Biopharmaceutical CMO and CRO Market Company Share Analysis
- 13.2. Competition Matrix
- 13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
- 13.2.2. New Product Launches and Product Enhancements
- 13.2.3. Mergers And Acquisition In Global Biopharmaceutical CMO and CRO Market
- 13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
- CHAPTER 14. Company Profile
- 14.1. Catalent, Inc.
- 14.1.1. Company Snapshot
- 14.1.2. Business Overview
- 14.1.3. Financial Overview
- 14.1.3.1. Revenue (USD Million), 2023
- 14.1.3.2. Catalent, Inc. 2023 Biopharmaceutical CMO and CRO Business Regional Distribution
- 14.1.4. Product /Service and Specification
- 14.1.5. Recent Developments & Business Strategy
- 14.2. Lonza Group AG
- 14.3. Patheon N.V.
- 14.4. Thermo Fisher Scientific Inc.
- 14.5. WuXi AppTec Co., Ltd.
- 14.6. Samsung Biologics
- 14.7. Boehringer Ingelheim GmbH
- 14.8. Cytovance Biologics, Inc.
- 14.9. AbbVie Contract Manufacturing
- 14.10. Fujifilm Diosynth Biotechnologies
- 14.11. AGC Biologics
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
